Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

GW-273227, a sodium channel blocker for the treatment of pain

Sep. 17, 1998

Glaxo Wellcome studies lamotrigine analogues in the search for new anticonvulsants

Sep. 17, 1998

Astra Arcus develops first full, selective alpha7 nAChR agonist

Sep. 17, 1998

Selective 5-HT2C antagonist selected for development at Organon

Sep. 17, 1998

European marketing application for Myotrophin withdrawn

Sep. 16, 1998

Algos releases phase III clinical trial results for MorphiDex

Sep. 16, 1998

Merck KGaA discovers potent dual 5-HT1A antagonist and 5-HT reuptake inhibitor

Sep. 16, 1998

S-23751: new 5-HT1A/5-HT7 receptor ligand with anxiolytic activity

Sep. 16, 1998

Potent and selective 5-HT1B/1D antagonists designed by Merck KGaA

Sep. 16, 1998

Arylsulfonamides as inhibitors of PLA2, cytokine release and neurodegeneration

Sep. 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Taiwan biotech looks outward in next phase of growth
BioWorld
Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to...